Second-Generation Antipsychotic Drug Use Among Medicaid-Enrolled Children: Quality-of-Care Concerns (OEI-07-12-00320)

The report was released in March 2015 by the Office of the Inspector General (OIG) for the federal Department of Health and Human Services (HHS). The OIG reviewed Medicaid fee-for-service (FFS) claims in five states for second-generation antipsychotics (SGAs) prescribed to children ages 0 to 17. The OIG selected a sample of 687 claims for SGAs prescribed between January 1, and June 30, 2011 to children in California, Florida, Illinois, New York, and Texas. Across the five states, during the period under review there were a total of 84,645 children with one or more Medicaid FFS . . .